首页> 外文期刊>Clinical ophthalmology >Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
【24h】

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

机译:抗青光眼前列腺素(PG)模拟眼科制剂中添加剂的安全性比较

获取原文
           

摘要

Purpose: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents).Methods: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan?; latanoprost), tafluprost (Tapros?; tafluprost), bimatoprost (Lumigan?; bimatoprost), travoprost (Travatan?; travoprost), travoprost (Travatan Z?; travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo).Results: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively.Conclusion: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK.
机译:目的:研究五种抗青光眼前列腺素类似物眼用制剂的安全性,并根据所含添加剂(防腐剂和表面活性剂)阐明它们的区别。方法:以下五种眼药水和三种添加剂是:被调查的:拉坦前列素(Xalatan ?;拉坦诺前列素),塔氟普罗斯特(Tapros ?; tafluprost),比马前列素(Lumigan ?;比马前列素),特拉沃前列素(Travatan ?; travoprost),特拉沃前列素(Travatan Z ?; travoprostkon-Z)(B) ,聚氧乙烯硬化蓖麻油40(HCO-40)和聚山梨酯80(P-80)。将这些实验溶液暴露于兔源角膜细胞系的培养细胞中一定时间,然后计算暴露时间,该时间造成50%细胞损伤(CD50),以活细胞与总细胞的比例表示(体外)。此外,在体内测量角膜抵抗力(CR)并计算CR比值(治疗后CR /治疗前CR×100)。结果:每种药物的CD50最长的是使用tafluprost,其次是travoprost-Z,比马前列素,travoprost和latanoprost。 0.005%,0.01%和0.02%BAK的CD50分别为14.5分钟,8.1分钟和4.0分钟。暴露于HCO-40后8分钟和暴露于P-80 30分钟后,存活细胞的数量降至60%。曲伐前列素的CR率为81.0%,拉坦前列素的CR为82.0%,表明治疗后CR显着降低(P <0.05)。 tafluprost,travoprost-Z或bimatoprost治疗后CR比率并未降低。 BAK的CR比率分别为0.005%,0.01%和0.02%,分别为105.0%,90.5%和68.7%,HCO-40和P-80的CR比率分别为108.7%和114.2%。 HCO-40和P-80被认为与每种眼药水引起的角膜损伤有关。使用HCO-40和P-80时,由于表面作用而导致角膜损伤。当HCO-40与BAK结合使用时,它会诱导胶束BAK并减少BAK对角膜的伤害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号